The Prostate Cancer Charity comments on NICE revision of draft denosumab ruling

The Prostate Cancer Charity expresses disappointment at the National Institute of Clinical Excellence's (NICE) decision to reverse its recommendation that denosumab be made available on the NHS in England and Wales to help minimise the risk of complications once prostate cancer has spread to a man's bones.

The Prostate Cancer Charity expresses disappointment at the National Institute of Clinical Excellence's (NICE) decision to reverse its recommendation that denosumab be made available on the NHS in England and Wales to help minimise the risk of complications once prostate cancer has spread to a man's bones.

Owen Sharp, Chief Executive of The Prostate Cancer Charity said: "It is extremely disappointing that NICE has reversed its recommendation to provide men with very advanced prostate cancer a drug that can help prevent painful complications. Although we understand the technical reasons for this decision, we would nevertheless urge NICE to revisit its clinical guidance for men with advanced prostate cancer to ensure they are able to access treatments that can improve their quality of life as they approach the end of their life."